BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36244466)

  • 1. Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma.
    Lin X; Shi Q; Yang XJ
    Hum Pathol; 2022 Dec; 130():36-46. PubMed ID: 36244466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
    Jia L; Jiang Y; Michael CW
    Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NKX3.1 as a marker of prostatic origin in metastatic tumors.
    Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
    Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry in diagnostic surgical pathology of the prostate.
    Hameed O; Humphrey PA
    Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
    Fonseca-Alves CE; Kobayashi PE; Rivera Calderón LG; Felisbino SL; Rinaldi JC; Drigo SA; Rogatto SR; Laufer-Amorim R
    PLoS One; 2018; 13(6):e0199173. PubMed ID: 29894516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine differentiation in prostate cancer.
    Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
    Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostatic adenocarcinoma metastases mimicking small cell carcinoma on fine-needle aspiration.
    Parwani AV; Ali SZ
    Diagn Cytopathol; 2002 Aug; 27(2):75-9. PubMed ID: 12203872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.
    Gan Q; Joseph CT; Guo M; Zhang M; Sun X; Gong Y
    Am J Clin Pathol; 2019 Sep; 152(4):495-501. PubMed ID: 31175351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
    Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic Study of Gleason Pattern 5 Prostatic Adenocarcinoma With "Single-cell" Growth Reveals 2 Distinct Types, One With "Plasmacytoid" Features.
    Nguyen JK; Chen YY; Magi-Galluzzi C; McKenney JK
    Am J Surg Pathol; 2020 Dec; 44(12):1635-1642. PubMed ID: 32991340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Xiao GQ; Ho G; Suen C; Hurth KM
    Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63.
    McCluggage WG; Kennedy K; Busam KJ
    Am J Surg Pathol; 2010 Apr; 34(4):525-32. PubMed ID: 20182342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
    Gordetsky J; Epstein JI
    Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic features of primary renal neuroendocrine carcinoma].
    Wang XH; Lu X; He B; Jiang YX; Yu WJ; Wang H; Zhang W; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):851-856. PubMed ID: 30423609
    [No Abstract]   [Full Text] [Related]  

  • 17. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas.
    Yu S; Hornick JL; Gonzalez RS
    Virchows Arch; 2021 Sep; 479(3):481-491. PubMed ID: 33733343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
    Simon RA; di Sant'Agnese PA; Huang LS; Xu H; Yao JL; Yang Q; Liang S; Liu J; Yu R; Cheng L; Oh WK; Palapattu GS; Wei J; Huang J
    Hum Pathol; 2009 Feb; 40(2):252-8. PubMed ID: 18835619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases.
    Mai KT; Roustan Delatour NL; Assiri A; Al-Maghrabi H
    Diagn Cytopathol; 2007 Feb; 35(2):91-5. PubMed ID: 17230567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.